317321-86-1

Basic information

• Product Name: benzyl 2-(2,6-dimethylanilino)-1-(1H-indol-3-ylmethyl)-2-oxoethylcarbamate
• Synonyms: benzyl 2-(2,6-dimethylanilino)-1-(1H-indol-3-ylmethyl)-2-oxoethylcarbamate
• CAS NO: 317321-86-1
• Molecular Formula: C27H27N3O3
• Molecular Weight: 441.52158
• Mol File: 317321-86-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: benzyl 2-(2,6-dimethylanilino)-1-(1H-indol-3-ylmethyl)-2-oxoethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 2-(2,6-dimethylanilino)-1-(1H-indol-3-ylmethyl)-2-oxoethylcarbamate(317321-86-1)
• EPA Substance Registry System: benzyl 2-(2,6-dimethylanilino)-1-(1H-indol-3-ylmethyl)-2-oxoethylcarbamate(317321-86-1)

Safety Data

• Hazardous Substances Data: 317321-86-1(Hazardous Substances Data)

Upstream product

• 87-62-7 2,6-dimethylaniline 
• 7432-21-5 N-carbobenzyloxy-L-tryptophane 
• 15142-91-3 rac-3-(1H-indol-3-yl)-2-methylpropanoic acid 
• 501-53-1 benzyl chloroformate 
• 54-12-6 Trp 
• 5241-64-5 BOC-tryptophane 

Relevant articles and documents

A class of DL-tryptophan compounds, preparation method and applications thereof

The invention provides a DL-tryptophan compound represented by a general formula I or a pharmaceutically acceptable salt thereof, a preparation method and applications thereof, especially applicationsin preparation of RANKL inhibitors. According to the DL-tryptophan compound or the pharmaceutically acceptable salt thereof, an OPG-RANKL-RANK signal system can be intervened by inhibiting the interaction of RANKL-RANK, and the activity of RANKL in osteoclast precursor cells is regulated and controlled, so that formation of osteoclasts is inhibited, and bone resorption is reduced; and the DL-tryptophan compound or the pharmaceutically acceptable salt thereof is expected to play a role in preventing and treating bone metabolic diseases, and brings good news to bone metabolic disease patients.

Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL) - Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization

Targeting RANKL/RANK offers the possibility of developing novel therapeutic approaches to treat bone metabolic diseases. Multiple efforts have been made to inhibit RANKL. For example, marketed monoclonal antibody drug Denosumab could inhibit the maturation of osteoclasts by binding to RANKL. This study is an original approach aimed at discovering small-molecule inhibitors impeding RANKL/RANK protein interaction. We identified compound 34 as a potent and selective RANKL/RANK inhibitor by performing structure-based virtual screening and hit optimization. Disruption of the RANKL/RANK interaction by 34 effectively inhibits RANKL-induced osteoclastogenesis and bone resorption. The expression of osteoclast marker genes was also suppressed by treatment of 34. Furthermore, 34 markedly blocked the NFATc1/c-fos pathway. Thus, our current work demonstrates that the chemical tractability of the difficult PPI (RANKL/RANK) target by a small-molecule compound 34 offers a potential lead compound to facilitate the development of new medications for bone-related diseases.

Synthesis and in vitro activities of NK-1 antagonists derived from L-tryptophan

A study of structure-activity relationships of a series of L-tryptophan derivative NK-1 antagonist was performed using 3,5-bis(trifluoromethyl)benzyl ester of N-acetyl-L-Tryptophan (IV) as a starting point. The ester moiety was replaced with several amidi